United States Drug Patent 6,787,529: Scope, Claims, Expiration, and Patent Landscape

U.S. Patent No. 6,787,529 protects substantially non-aqueous topical gels combining a vitamin D analogue, a corticosteroid, a viscosity-increasing excipient, and specified solvent classes. The broadest practical commercial embodiment is a calcipotriol and betamethasone dipropionate gel or suspension stabilized with polyoxypropylene-15-stearyl ether and hydrogenated castor oil. The patent issued September 7, 2004, and expired in 2020. It no longer creates an enforceable U.S. patent barrier to generic development.

The patent remains relevant as an historical basis for the Taclonex and related calcipotriol/betamethasone product platforms. Current competition is governed primarily by later formulation, delivery-system, and product-specific patents rather than by U.S. Patent 6,787,529.

What does U.S. Patent 6,787,529 protect?

The patent protects a topical pharmaceutical composition with five core elements:

A substantially non-aqueous gel.
At least one listed vitamin D analogue.
At least one corticosteroid.
A viscosity-increasing excipient producing a viscosity of approximately 5 to 500 mPa.s.
At least one solvent selected from six defined chemical classes.
Stability after storage at 40°C for three months.

The independent composition claim is claim 1. Claim 20 is an independent-looking method claim, but it depends on claim 1 and therefore requires use of a composition satisfying every limitation of claim 1.

The patent does not broadly cover every topical combination of calcipotriol and a corticosteroid. A competing product must satisfy the claim's physical, compositional, solvent, and stability limitations for literal infringement.

What active ingredients are covered?

The vitamin D analogue Markush group includes:

Seocalcitol
Calcipotriol
Calcipotriol hydrate
Calcitriol
Tacalcitol
Maxacalcitol
Paricalcitol
Falecalcitriol
1α,24S-dihydroxy-vitamin D2
A specified synthetic vitamin D analogue identified by its chemical structure

The corticosteroid group includes betamethasone, clobetasol, clobetasone, desoximethasone, diflucortolone, diflorasone, fluocinonide, flumethasone, fluocinolone, fluticasone, fluprednidene, halcinonide, hydrocortisone, mometasone, and triamcinolone, including specified esters, acetonides, and mixtures.

The commercial center of gravity is calcipotriol or calcipotriol hydrate combined with betamethasone dipropionate.

How do the claims divide between broad and narrow coverage?

Claim 1: the principal composition claim

Claim 1 is broad in its active-ingredient selection but narrow in its formulation architecture. It requires all of the following:

Limitation	Practical significance
Substantially non-aqueous gel	Excludes ordinary aqueous creams and many emulsions
Vitamin D analogue	Includes calcipotriol and several other analogues
Corticosteroid	Includes numerous dermatological corticosteroids
Viscosity of 5-500 mPa.s	Creates a measurable physical limitation
Specified solvent class	Limits the excipient system to defined chemical families
Stability at 40°C for three months	Creates a storage-stability requirement

The term "comprising" permits additional excipients, surfactants, antifungals, preservatives, fragrances, and other ingredients. A formulation may therefore infringe even if it contains ingredients not listed in claim 1, provided it still contains the required elements.

Claims 2 through 8: viscosity and solvent limitations

Claims 2 through 8 narrow the formulation as follows:

Claim 2 limits viscosity to approximately 10 to 250 mPa.s.
Claim 3 requires a thixotropic gelling agent.
Claim 4 identifies hydrogenated castor oil as the thixotropic agent.
Claim 5 covers wax, polyethylene, or microcrystalline wax as the viscosity-increasing excipient.
Claim 6 narrows the solvent to compounds of formula H(OCH2C(R1)H)xOR2.
Claim 7 requires methyl substitution for R1.
Claim 8 identifies polyoxypropylene-15-stearyl ether.

These claims target a pourable or spreadable scalp and skin formulation rather than a conventional high-viscosity ointment.

Claims 9 through 13: active-ingredient limitations

Claims 9 through 13 narrow the active ingredients and steroid structures. Claim 11 focuses on calcipotriol or its hydrate. Claim 12 covers specified corticosteroids, and claim 13 identifies particular ester and acetonide forms.

Claim 11 is commercially important because it captures the calcipotriol component used in calcipotriol/betamethasone products. Claim 12 and claim 13 narrow the steroid component but do not require betamethasone dipropionate alone.

Claims 14 and 15: concentration and formulation-specific protection

Claim 14 covers compositions containing:

0.001 to 0.25 mg/g or mL of vitamin D analogue; and
0.05 to 2 mg/g or mL of corticosteroid.

Claim 15 is substantially narrower and recites a defined composition per gram:

Ingredient	Amount
Betamethasone, supplied as dipropionate	0.643 mg
Betamethasone active equivalent	0.5 mg
Calcipotriol, supplied as hydrate	52.2 micrograms
Calcipotriol active equivalent	50 micrograms
Polyoxypropylene-15-stearyl ether	170 mg
Hydrogenated castor oil	30 mg
Heptamethylnonane	Quantity sufficient to 1 g

This claim corresponds to the familiar 0.005% calcipotriol and 0.064% betamethasone dipropionate strength used in branded products. Because it recites defined ingredients and quantities, claim 15 is easier to design around than claim 1.

Claims 16 through 19: antifungal and scalp formulations

These claims add:

An antifungal agent.
Scalp administration.
A surfactant.
Specified octoxynol, nonoxynol, or polyoxyethylene C12-22 alkyl ether surfactants.

The scalp claims address delivery challenges associated with hair-bearing skin. A competing scalp product that uses a different surfactant system may avoid claims 18 and 19 while remaining potentially relevant to claim 1.

Claims 20 through 23: methods of treatment

The method claims cover treating psoriasis or sebo-psoriasis of the scalp by applying the claimed composition once or twice daily, including once-daily administration.

The method claim does not independently cover use of any calcipotriol/corticosteroid product. It requires use of a composition that meets claim 1. A product that has the same active ingredients but uses an aqueous cream, aerosol foam, or a non-listed solvent may fall outside the method claims.

What formulation is exemplified by U.S. Patent 6,787,529?

The key formulation is a low-viscosity, substantially non-aqueous gel containing:

Calcipotriol hydrate
Betamethasone dipropionate
Polyoxypropylene-15-stearyl ether
Hydrogenated castor oil
Heptamethylnonane

The formulation uses hydrogenated castor oil to generate structure and thixotropy. Polyoxypropylene-15-stearyl ether acts as a solvent and contributes to solubilization and skin delivery. Heptamethylnonane functions as a nonpolar carrier or emollient component.

The claim architecture reflects a formulation problem: vitamin D analogues and corticosteroids must remain chemically stable in a topical vehicle while preserving acceptable spreading, scalp application, and once-daily usability. The 40°C/three-month stability requirement is central to the claimed performance profile.

When did U.S. Patent 6,787,529 expire?

U.S. Patent 6,787,529 expired in 2020. Public patent records identify June 11, 2020, as the expiration date for the U.S. patent term. The patent is therefore not an active U.S. exclusion right for composition, method, or manufacturing activities covered solely by this patent. [1]

Event	Date
Earliest priority date	June 11, 1999
U.S. grant	September 7, 2004
Patent term expiration	June 11, 2020
Current enforceability	Expired

The expiration does not eliminate possible exposure under later patents covering specific foams, emulsions, vehicles, delivery systems, manufacturing processes, or approved product variants.

What is the Orange Book status of U.S. Patent 6,787,529?

The patent was associated with the U.S. regulatory and commercial history of calcipotriol/betamethasone topical products, including Taclonex-related products. The Orange Book must be evaluated by product and dosage form because a patent listed for an ointment, topical suspension, or foam does not automatically apply to every product containing the same active ingredients. [2]

The regulatory distinction is material:

Product type	Active ingredients	Patent relevance
Ointment	Calcipotriol and betamethasone dipropionate	Earlier combination-product patents and formulation patents
Topical suspension	Calcipotriol and betamethasone dipropionate	U.S. Patent 6,787,529 is relevant historically
Aerosol foam	Calcipotriene and betamethasone dipropionate	Later foam and delivery patents are more relevant
Cream	Calcipotriene and betamethasone dipropionate	Later vehicle and formulation patents may apply

The patent's expiration means it should not create a current Orange Book blocking position by itself. A current ANDA applicant would still need to review every unexpired patent listed for the reference product and determine whether Paragraph IV certifications are required.

Were there Paragraph IV challenges to this patent?

A Paragraph IV certification would have been relevant while U.S. Patent 6,787,529 remained listed and unexpired. After expiration in 2020, the patent no longer supports a statutory 30-month stay based on a new Paragraph IV challenge.

Publicly available regulatory records do not establish an active Paragraph IV dispute against this patent today. Any historical ANDA challenge must be analyzed against the product-specific Orange Book listing, the filing date, and the patent status at that time. A generic applicant now receives no remaining patent term from U.S. Patent 6,787,529 itself.

The strongest historical invalidity and non-infringement positions would have focused on:

Prior topical combinations containing a vitamin D analogue and corticosteroid.
Failure to meet the specified solvent classes.
Aqueous or emulsion-based formulations outside the "substantially non-aqueous" limitation.
Viscosity outside the claimed range.
Failure to demonstrate the 40°C/three-month stability limitation.
Formulations using a different gelling system.

What patent litigation affects the calcipotriol/betamethasone market?

U.S. Patent 6,787,529 is no longer an active litigation asset. Litigation risk for current products depends on later patents covering formulation and delivery technology.

The main commercial categories are:

Earlier combination patents

Earlier patents covering vitamin D analogue and corticosteroid combinations established the basic therapeutic combination and related ointment technology. U.S. Patent No. 5,849,726 is part of this historical landscape. Its value was directed to earlier combination-product protection and has expired. [3]

Gel and suspension patents

U.S. Patent 6,787,529 addressed a substantially non-aqueous gel or suspension-like vehicle with defined solvents, viscosity, and stability. It is now expired.

Foam patents

Enstilar is an aerosol foam containing calcipotriene and betamethasone dipropionate. Its formulation, propellant system, foam structure, and manufacturing process are distinct from the low-viscosity gel described in U.S. Patent 6,787,529. Later patents, rather than the expired gel patent, are the relevant risk for a foam competitor. [4]

Cream patents

Wynzora is a cream formulation containing calcipotriene and betamethasone dipropionate. Its PAD Technology and vehicle design differ from the solvent and gelling system claimed in U.S. Patent 6,787,529. A cream developer must conduct a separate patent review focused on the product's vehicle, emulsion structure, manufacturing process, and Orange Book-listed patents. [5]

How strong is the patent estate for U.S. Patent 6,787,529?

As an expired patent, its current exclusionary strength is zero. Its historical claim strength was mixed.

Issue	Assessment
Breadth of active-ingredient list	Broad
Breadth of solvent definition	Moderate to broad
Physical-form limitation	Narrowing
Stability limitation	Potentially difficult to prove
Claim 15 commercial specificity	Narrow
Scalp-use claims	Narrow to moderate
Current enforceability	None
Design-around potential during term	Meaningful

The patent was strongest against a product that copied the full formulation concept: calcipotriol hydrate, betamethasone dipropionate, polyoxypropylene-15-stearyl ether, hydrogenated castor oil, heptamethylnonane, and the claimed viscosity and stability profile.

It was weaker against:

Aqueous creams.
Aerosol foams.
Formulations using alternative solvents.
Vehicles with viscosity above or below the claimed range.
Products using alternative gelling agents.
Products using different active ingredients.
Formulations lacking the required three-month stability evidence.

What generic launch scenarios exist after expiration?

The expiration of U.S. Patent 6,787,529 creates several potential launch pathways:

A generic topical suspension or gel can replicate the active ingredients while changing the solvent or gelling system.
A generic cream can use an emulsion architecture outside the substantially non-aqueous gel claims.
A generic scalp product can use a different surfactant and vehicle system.
A manufacturer can develop a product with the same strength but a different delivery platform.
An applicant can pursue an ANDA where the reference product and listed patent portfolio permit a direct generic pathway.
A 505(b)(2) applicant can pursue a modified vehicle, dosage form, or delivery system where clinical or bridging requirements differ from an ANDA.

The principal remaining obstacles are regulatory equivalence, product-specific unexpired patents, formulation know-how, stability data, and manufacturing scale-up.

What manufacturing and intellectual-property barriers remain?

The expired patent does not eliminate technical barriers. A competing manufacturer still must control:

Uniform dispersion of low-dose calcipotriol.
Chemical stability of calcipotriol and betamethasone dipropionate.
Reproducible viscosity and thixotropy.
Homogeneity over shelf life.
Scalp spreading and washability.
Microbiological quality where the formulation requires it.
Packaging compatibility.
Scale-up of hydrogenated castor oil or alternative structuring agents.
Stability at accelerated and long-term conditions.

Manufacturing know-how may remain protected as trade secrets even when the patent claims are public and expired. The strongest practical barrier may therefore be process reproducibility rather than U.S. patent exclusivity.

How does U.S. Patent 6,787,529 compare with later calcipotriol/betamethasone products?

Attribute	U.S. 6,787,529 formulation	Enstilar foam	Wynzora cream
Active ingredients	Calcipotriol and betamethasone dipropionate	Calcipotriene and betamethasone dipropionate	Calcipotriene and betamethasone dipropionate
Vehicle	Substantially non-aqueous gel	Aerosol foam	Cream
Key delivery issue	Low-viscosity gel stability and scalp use	Foam generation and skin deposition	Cream vehicle and absorption
Core patent relevance	Expired	Later foam patents	Later cream and vehicle patents
Generic risk	No current risk from this patent	Product-specific patents remain relevant	Product-specific patents remain relevant

Key Takeaways

U.S. Patent 6,787,529 covers a defined non-aqueous topical gel architecture, not every calcipotriol/corticosteroid product.
Claim 1 requires a vitamin D analogue, corticosteroid, viscosity-increasing excipient, specified solvent class, claimed viscosity, and 40°C/three-month stability.
Claim 15 targets a commercially significant calcipotriol/betamethasone dipropionate formulation.
Claims 20 through 23 cover treatment of psoriasis or scalp sebo-psoriasis with the claimed composition.
The patent expired June 11, 2020.
It no longer supports a current U.S. patent injunction, Paragraph IV stay, or Orange Book exclusivity period.
Current competitive risk rests on later patents for foam, cream, vehicle, delivery, manufacturing, and product-specific formulations.
A generic developer can avoid the expired claims through changes to the vehicle, solvent, viscosity, gelling system, or dosage form, subject to later patent review and FDA requirements.

FAQs About U.S. Patent 6,787,529

Does U.S. Patent 6,787,529 cover Taclonex?

It historically covered formulations corresponding to the calcipotriol and betamethasone dipropionate topical platform, including the claimed non-aqueous gel architecture. The patent expired in 2020.

Can a company launch a calcipotriol/betamethasone generic based only on this patent's expiration?

No. The expired patent removes one barrier, but the applicant must review all current Orange Book listings, later formulation patents, regulatory requirements, and reference-product exclusivity.

Does claim 1 cover an aqueous calcipotriol and betamethasone cream?

Generally, an ordinary aqueous cream would not satisfy the "substantially non-aqueous pharmaceutical gel" limitation. The complete formulation must still be assessed under the claim language and equivalents doctrine.

Does the patent cover a calcipotriol/betamethasone foam?

Not as a typical product category. A foam may lack the claimed gel structure, viscosity profile, and solvent system. Later foam patents can create separate protection.

Is the 40°C stability requirement a meaningful infringement limitation?

Yes. A formulation must satisfy the claimed stability condition. The requirement can affect both literal infringement analysis and the evidentiary burden in litigation.

Sources

U.S. Patent No. 6,787,529, Pharmaceutical composition comprising a vitamin D analogue and a corticosteroid (2004). U.S. Patent and Trademark Office. https://patents.google.com/patent/US6787529B2/en
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Patent No. 5,849,726, Pharmaceutical composition comprising a vitamin D analogue and a corticosteroid (1998). U.S. Patent and Trademark Office. https://patents.google.com/patent/US5849726
U.S. Food and Drug Administration. (2015). Enstilar prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207589s000lbl.pdf
U.S. Food and Drug Administration. (2020). Wynzora prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213325s000lbl.pdf

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	380542	⤷ Start Trial
Australia	2001291637	⤷ Start Trial
Australia	9163701	⤷ Start Trial
Brazil	0114927	⤷ Start Trial
Canada	2423930	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,787,529

Summary for Patent: 6,787,529